A pan-cancer analysis of LSM2 expression using the GEPIA database revealed significantly higher expression of LSM2 in tumour samples compared to normal samples across various cancer types, including glioblastoma (GBM) and lower-grade glioma (LGG) (p < 0.05) (Figure 2A). Here, LSM2 is linked to neoplasm.